NCT03376477: A trial that was reported late by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
This trial has reported, although it was 174 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT03376477 |
|---|---|
| Title | A Randomized, Double-blind, Placebo-Controlled Phase II Trial of an Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Sept. 23, 2019 |
| Completion date | Jan. 2, 2024 |
| Required reporting date | Jan. 1, 2025, midnight |
| Actual reporting date | June 25, 2025 |
| Date last checked at ClinicalTrials.gov | June 15, 2026 |
| Days late | 174 |